Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093939 | 0.91 | PPARA (0.62) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3812770 | 0.90 | PPARA (0.65) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1221911 | 0.87 | PPARA (0.61) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8605589 | 0.87 | PPARA (0.57) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8605187 | 0.87 | PPARA (0.57) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7686496 | 0.85 | PPARA (0.64) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7502255 | 0.85 | PPARA (0.60) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27880443 | 0.85 | PPARA (0.60) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7505230 | 0.85 | PPARA (0.64) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25801694 | 0.85 | PPARA (0.64) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384013-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173485-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-03 | — | — | EP | disclosed |
| CN-107108527-B | Ataxia telangiectasia and Rad 3-Associated (ATR) protein kinase inhibitors | 阿特林制药有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-3207031-B1 | ATAXIA TELENGIECTASIA AND RAD3-RELATED (ATR) PROTEIN KINASE INHIBITORS | Atrin Pharmaceuticals LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10308638-B2 | Selective alpha-7 nicotinic receptor agonists and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-04 | — | — | US | disclosed |
| US-10196405-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | Atrin Pharmaceuticals LLC (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180244653-A1 | SELECTIVE ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-08-30 | — | — | US | disclosed |
| US-9981989-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | Atrin Pharmaceuticals LLC (US) | 2018-05-29 | — | — | US | disclosed |
| CN-107108527-A | Ataxia telangiectasia and Rad 3-Associated (ATR) protein kinase inhibitors | 阿特林制药有限责任公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| US-20090170720-A1 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-07-02 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| US-7485468-B2 | Drug screening for inhibititors of extracellular matrix (ECM) degradation and inflammation using polypeptide and fragments, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA; measuring binding affinity; arthritis; matrix metalloprotease, cathepsin | GALAPAGOS BV (BE) | 2009-02-03 | — | — | US | disclosed |
| EP-1817411-A2 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-7052742-B1 | Five membered-ring compounds and utilization thereof in liquid crystal mixtures | CLARIANT INTERNATIONAL LTD. (CH) | 2006-05-30 | — | — | US | disclosed |
| US-20060094061-A1 | Drug screening for inhibititors of extracellular matrix (ECM) degradation and inflammation using polypeptide and fragments, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA; measuring binding affinity; arthritis; matrix metalloprotease, cathepsin | GALAPAGOS N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| WO-2006040357-A2 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1214316-A1 | FIVE MEMBERED-RING COMPOUNDS AND UTILIZATION THEREOF IN LIQUID CRYSTAL MIXTURES | CLARIANT INTERNATIONAL LTD. (CH) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016131-A2 | FIVE MEMBERED-RING COMPOUNDS AND UTILIZATION THEREOF IN LIQUID CRYSTAL MIXTURES | CLARIANT INTERNATIONAL LTD (CH) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308638-B2 | Selective alpha-7 nicotinic receptor agonists and methods for making and using them | CHRNA7, CHRNA1, CHRNA5 | PPARA 1523/4885KCNH2 224/4885NPC1 2067/4885 |
| US-10196405-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | CHEK2, ATR, CHEK1 | PPARA 3744/4885KCNH2 2277/4885NPC1 4202/4885 |
| US-20180244653-A1 | SELECTIVE ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | CHRNA7, CHRNA1, CHRNA5 | PPARA 1523/4885KCNH2 224/4885NPC1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.